(Morning News) The European Drug Administration (EMA) said on Friday (September 2) that there may be a new crown disease strain in winter, but the existing vaccine may occur, but the existing vaccineIt should be able to protect people from the effects of serious diseases and deaths.
Marco Cavaleri, head of the European Pharmacy Administration's vaccine strategy, said at a press conference that even if there are two vaccines that can be used for the opposite strains for Omikon, people are "You should not wait for a specific vaccine ... because there may be a new crown disease strain that we cannot predict today. "
On September 1, the European Pharmacy Administration recommended to approve two improved versions of BA.1 that can be targeted at Omikon subtype BA.1.Vaccinated over 12 years old.
The two vaccines are COMIRNATY vaccines based on the co -produced by the US Pfizer Pharmaceutical Company and the German BIONTECH company, and the Spikevax vaccine based on the US Modner.
Studies have shown that after three months of vaccination of the initial vaccine, the improved version of the vaccine can be used to stimulate a strong immune response to BA.1 and primitive coronal virus strains.In terms of reaction, it is more effective than initial vaccines.The side effects of the improved version of the vaccine are equivalent to the side effects of the initial vaccine, usually mild and short.
Cavaleri said that the improved version of vaccine is suitable for high -risk groups such as elderly people, vulnerable groups, pregnant women and medical staff.
In addition, the improved version of the Amitkon subtype BA.4 and BA.5 vaccine is currently being examined. If it is approved, the European Pharmacy Administration will further expand the available vaccine resources.
